Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Congqi Shi, Kaiyu Qin, Anqi Lin, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Qian Sun, Zhenya Hong, Cong Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 245
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors
Timothy A. Yap, Anthony W. Tolcher, Ruth Plummer, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2057-2067
Open Access | Times Cited: 10
Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-α signaling axis in triple-negative breast cancer
Chenying Liu, Xiaolong Qian, Chunyan Yu, et al.
Cancer Letters (2024) Vol. 586, pp. 216642-216642
Closed Access | Times Cited: 9
A new 4-gene-based prognostic model accurately predicts breast cancer prognosis and immunotherapy response by integrating WGCNA and bioinformatics analysis
Wenlong Chen, Yakun Kang, Wenyi Sheng, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 9
Pembrolizumab and olaparib in a cisplatin-refractory testicular cancer patient with a high TMB: first case report
Nils C. H. van Creij, Gerald Klinglmair, Leonhard Gruber, et al.
Therapeutic Advances in Urology (2025) Vol. 17
Open Access | Times Cited: 1
Unlocking the potential of T‐cell metabolism reprogramming: Advancing single‐cell approaches for precision immunotherapy in tumour immunity
Lihaoyun Huang, Haitao Li, Cangang Zhang, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 3
Open Access | Times Cited: 6
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
Xin Su, Jian Li, Xiao‐Ming Xu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
DNA Repair Deficiency Regulates Immunity Response in Cancers: Molecular Mechanism and Approaches for Combining Immunotherapy
Yi Xu, Somaira Nowsheen, Min Deng
Cancers (2023) Vol. 15, Iss. 5, pp. 1619-1619
Open Access | Times Cited: 16
Identification of the key DNA damage response genes for predicting immunotherapy and chemotherapy efficacy in lung adenocarcinoma based on bulk, single-cell RNA sequencing, and spatial transcriptomics
Shijie Sun, Kai Wang, Deyu Guo, et al.
Computers in Biology and Medicine (2024) Vol. 171, pp. 108078-108078
Closed Access | Times Cited: 5
A carrier-free supramolecular nano-twin-drug for overcoming irinotecan-resistance and enhancing efficacy against colorectal cancer
Miaomiao Yuan, Tong Chen, Lü Jin, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 11
Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors
Bradford A. Perez, Raid Aljumaily, Thomas U. Marron, et al.
ESMO Open (2024) Vol. 9, Iss. 2, pp. 102217-102217
Open Access | Times Cited: 4
Pancancer analysis of the prognostic and immunological role of FANCD2: a potential target for carcinogenesis and survival
Zedan Zhao, Ruyu Wang, Ruixue Wang, et al.
BMC Medical Genomics (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
DNA damage response-related signatures characterize the immune landscape and predict the prognosis of HCC via integrating single-cell and bulk RNA-sequencing
Hanqi Li, Yu Shi, Yue Li, et al.
International Immunopharmacology (2024) Vol. 137, pp. 112475-112475
Open Access | Times Cited: 4
Exploring potential treatment opportunities in a head and neck tumor patient with AdCC: A novel germline ERCC2 mutation case report
Yuanhao Liu, Tiantian Han, Didi Guo, et al.
Medicine (2025) Vol. 104, Iss. 1, pp. e41233-e41233
Open Access
Pyrithione zinc alters mismatch repair to trigger tumor immunogenicity
Huanling Zhang, Jiaxin Wu, Lei Cui, et al.
Oncogene (2025)
Closed Access
Decoding the mechanisms behind second primary cancers
Meiyuan Zeng, Anqi Lin, Aimin Jiang, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
UVC-Induced Oxidative Stress and DNA Damage Repair Status in Head and Neck Squamous Cell Carcinoma Patients with Different Responses to Nivolumab Therapy
Christina Papanikolaou, Panagiota Economopoulou, Niki Gavrielatou, et al.
Biology (2025) Vol. 14, Iss. 2, pp. 195-195
Open Access
MYC amplification sensitizes TNBC to CHK1 inhibitors
Bin Li, Tiantian Liu, Mingchuan Zhao, et al.
Cellular Signalling (2025) Vol. 131, pp. 111709-111709
Closed Access
Identification of DNA damage and repair gene-related markers in pancreatic ductal adenocarcinoma by single-cell and bulk RNA sequencing
Chao-Yi Zhang, Rong Tang, Jianhui Yang, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
NK Cell Senescence in Cancer: From Molecular Mechanisms to Therapeutic Opportunities
Zhiquan Qiu, Zhengrui Li, Cangang Zhang, et al.
Aging and Disease (2025)
Open Access
Inhibition of Checkpoint Kinase 1 (CHK1) Upregulates Interferon Regulatory Factor 1 (IRF1) to Promote Apoptosis and Activate Anti-Tumor Immunity via MICA in Hepatocellular Carcinoma (HCC)
Xicai Li, Jingquan Huang, Qiulin Wu, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 850-850
Open Access | Times Cited: 8
ATM Inhibition-Induced ISG15/IFI27/OASL Is Correlated with Immunotherapy Response and Inflamed Immunophenotype
Chi-Han Huang, Yun-Cian Huang, Jun-Kai Xu, et al.
Cells (2023) Vol. 12, Iss. 9, pp. 1288-1288
Open Access | Times Cited: 7
Recent advancements in cGAS-STING activation, tumor immune evasion, and therapeutic implications
Md Saiful Islam, Mohammad Saiful Islam, Mst Rubaiat Nazneen Akhand, et al.
Medical Oncology (2024) Vol. 41, Iss. 11
Closed Access | Times Cited: 2
The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer
Deqian Xie, Bowen Jiang, Shijin Wang, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 5
Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy
Kenneth K.W. To, William C. Cho
Pharmaceutics (2023) Vol. 15, Iss. 8, pp. 2166-2166
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top